文献速递肿瘤 PET/CT

18F-PSMA-1007 PET/CT 在生化复发前列腺癌患者中的诊断性能

Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-07-20

本回顾性分析纳入100例生化复发前列腺癌患者,注射338±44.31 MBq 18F-PSMA-1007后120分钟行全身PET/CT。95%患者至少一处病理性发现,PSA≤0.5 ng/ml组病理性扫描率仍达86%,PSA>2.0 ng/ml组中位SUVmax显著高于其他PSA组。

要点

  • 100例生化复发患者中95例(95%)18F-PSMA-1007 PET/CT示至少一处病理性发现。
  • PSA≤0.5、0.51-1.0、1.1-2.0、>2.0 ng/ml组病理性扫描率分别为86%、89%、100%、100%。
  • PSA>2.0 ng/ml组中位SUVmax显著高于其他所有PSA组。

核心结论

  • 18F-PSMA-1007 PET/CT可在高比例生化复发患者中检出复发性前列腺癌。
  • 即使PSA水平低至≤0.5 ng/ml,18F-PSMA-1007 PET/CT病理性扫描概率似乎仍较高,作者认为这可能对该组患者的管理产生显著影响。

研究设计与样本

  • 回顾性分析纳入100例连续生化复发前列腺癌患者,平均年龄68.75±7.6岁。
  • 所有患者注射338±44.31 MBq 18F-PSMA-1007后120分钟行全身PET/CT(从下肢至颅骨)。
  • 92%患者曾行前列腺切除术,45%曾行前列腺床放射治疗,27%曾行雄激素剥夺治疗;38例(38%)在手术基础上加行前列腺床放疗,10例(10%)接受过全部三种治疗。

主要发现

  • PSA≤0.5、0.51-1.0、1.1-2.0、>2.0 ng/ml组病理性扫描率分别为86%、89%、100%、100%。
  • 中位Gleason评分为7(范围5-10),有Gleason评分可用的患者中70例评分在7-9范围,该组病理性扫描率为93%(65/70)。
  • PSA≤0.5、0.51-1.0、1.1-2.0、>2.0 ng/ml组病理性发现的中位SUVmax分别为10.25、14.32、13.16、28.87。
  • PSA>2.0 ng/ml组中位SUVmax显著高于其他所有PSA组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The introduction of ligands targeting prostate-specific membrane antigen (PSMA), especially 68Ga-PSMA-11, has changed the management of patients with prostate cancer (PCa). 18F-Labelled ligands can be produced in larger amounts and therefore can improve availability for a larger group of patients. The aim of this study was to evaluate the diagnostic performance of the recently introduced 18F-PSMA-1007 in patients with recurrent PCa. METHODS: This retrospective analysis included 100 consecutive patients with biochemical relapse (mean age 68.75 ± 7.6 years) referred for PSMA PET/CT. Whole-body PET/CT imaging (from the lower limbs to the skull) was performed in all patients 120 min after injection of 338 ± 44.31 MBq 18F-PSMA-1007. Prostatectomy, radiation beam therapy of the prostate bed and androgen-deprivation therapy had been performed in 92%, 45% and 27% of the patients, respectively. Radiation beam therapy of the prostate bed had been performed in addition to surgery in 38 patients (38%) and 10 patients (10%) had received all three therapy modalities. The probability of a 18F-PSMA-1007 PET/CT scan suggestive of pathology was compared with the Gleason score (GS) and PSA level. RESULTS: Of the 100 patients, 95 (95%) showed at least one pathological finding on 18F-PSMA-1007 PET/CT. The overall median PSA level was 1.34 ng/ml (range 0,04-41.3 ng/ml). The rates of pathological scans were 86%, 89%, 100% and 100% among patients with PSA levels ≤0.5, 0.51-1.0, 1.1-2.0 and > 2.0 ng/ml, respectively. The median GS was 7 (range 5-10). The majority of patients (70) with a GS available had a score in the range 7-9. The rate of pathological scans in these patients was 93% (65/70). The median SUVmax values of the pathological findings were 10.25, 14.32, 13.16 and 28.87 in patients with PSA levels ≤0.5, 0.51-1.0, 1.1-2.0 and >2.0 ng/ml, respectively. The median SUVmax in patients with a PSA level of >2.0 ng/ml was significantly higher than in all other PSA groups. CONCLUSION: 18F-PSMA-1007 PET/CT can detect recurrent PCa in a high percentage of patients with biochemical relapse. The probability of a pathological 18F-PSMA-1007 PET/CT scan seems to be high even in patients with a low PSA level ≤0.5 ng/ml, and this may have a significant impact on the management of this relevant group of patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rahbar K, Afshar-Oromieh A, Seifert R, et al. Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 30027419. doi:10.1007/s00259-018-4089-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。